After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to unlock its next chapter of mental health treatment.
TEV’749 is a long-acting formulation of olanzapine, one of the most widely used atypical antipsychotic schizophrenia treatments to date. The drug was first approved in the 1990s and is currently marketed by Eli Lilly under the brand name Zyprexa.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,